Novo Nordisk, Septerna in $2.2b deal to develop oral molecules
HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team May 14, 2025: Novo Nordisk and Septerna, Inc., have inked a $2.2 billion global collaboration and licensing pact to develop oral.
HQ Team April 11, 2025: For people living with diabetes, glucose sensors for monitoring sugar levels are a game changer. The present ones.
HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.
HQ Team March 8, 2025: A study published in The Lancet by the Global Burden of Disease Study BMI Collaborators reveals alarming statistics.
Novo Nordisk’s medicine has been approved by the US drug regulator for reducing the risk of kidney failure and death due to cardiovascular.
Novo Nordisk A/S, a Danish pharmaceutical company, has expanded its agreement with US-based Valo Health Inc., almost to double the number of drugs.
HQ Team December 13, 2024: Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
Bharti Jayshankar December 5, 2024: Dark chocolate is a healthy indulgence allowed even for diabetics, with research supporting its benefits. Studies suggest that.
HQ Team November 9, 2024: A recent study indicates that rosuvastatin is associated with a slightly reduced risk of all-cause mortality and major.
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.